clinical trial · NCT05908695
An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.·phase4·recruiting·n = 1,312
Alzheimer's DiseaseGV-971Placebo
brief summary
The primary purpose of this study is to confirm the clinical efficacy and mechanism of action of GV-971, and identify incidence of known adverse reactions in long-term use and observe new adverse reactions, providing more guidance for clinical use.
started
Aug 31, 2023
primary completion
Jun 1, 2029
completion
Dec 1, 2029
last updated
Nov 9, 2023
official title
A 36-week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol